Comparative Analysis of Peptides vs. Traditional Anabolics

What This Page Compares

Traditional anabolic substances include a range of compounds beyond steroids. This page compares peptides with three of them: recombinant human growth hormone (HGH), insulin and direct IGF-1. HGH and IGF-1 sit on the same hormone axis that GH secretagogue peptides target, and insulin shares IGF-1's main acute risk, low blood sugar. Steroids appear in the tables for context; our peptides vs. AAS comparison covers them in depth.

Categories Compared

Peptides

Category	Examples	Primary Mechanism
GH Secretagogues	CJC-1295, Ipamorelin, GHRP-2	Stimulate natural GH release
Recovery Peptides	BPC-157, TB-500	Tissue repair pathways (mostly animal data)
Metabolic Peptides	MOTS-c, Fragment 176-191	Energy metabolism (mostly animal data)

Traditional Anabolics

Category	Examples	Primary Mechanism
AAS	Testosterone, Nandrolone	Androgen receptor activation
HGH	Recombinant GH	Direct GH replacement
Insulin	Rapid, long-acting	Nutrient partitioning
IGF-1	Mecasermin, LR3-IGF-1, MGF	Direct growth factor

As of October 2026, none of these peptides is approved as a drug in the US. Recombinant GH and insulin are prescription medicines, as is mecasermin (Increlex).

Detailed Comparison by Category

Peptides vs. HGH

Factor	GH Peptides	Recombinant HGH
Mechanism	Stimulate pituitary	Bypass pituitary
Pulsatile release	Preserved (CJC-1295 and MK-677 studies)	Set by the injected dose
Cost	Lower	Much higher
IGF-1 elevation	1.5-3x for 9-11 days after one CJC-1295 dose (2006 trial)	Dose-dependent
Side effects in trials	Appetite, mild edema, higher fasting glucose (MK-677)	Soft tissue edema, fatigue (2008 review)
Convenience	Short-acting GHRPs injected 1-3x daily (user reports)	Once daily

A 2008 systematic review of 27 small trials in fit young adults (mean HGH dose 36 mcg/kg per day, mostly for under a month) found about 2.1 kg more lean body mass than in controls. Strength and exercise capacity didn't clearly improve. In a 2-year trial of the oral secretagogue MK-677 (25 mg daily) in adults aged 60-81, fat-free mass rose about 1.1 kg with no change in strength or function. Fasting glucose rose about 5 mg/dL. Neither study enrolled trained lifters, and nobody has compared a secretagogue with HGH head to head.

Peptides vs. Insulin

Factor	Peptides	Insulin
Primary effect	GH/recovery pathways	Nutrient transport
Muscle gain potential	Lean mass without strength gain (MK-677)	No controlled trials in non-diabetics
Danger level	Low in trials so far	High (hypoglycemia)
Standalone use	Common (user reports)	Rare: 95% of surveyed users also took AAS

The insulin data come from a 2012 online survey of 41 non-diabetic insulin users recruited on bodybuilding forums. Most (56.8%) reported hypoglycemia and one reported losing consciousness. Respondents averaged about 16 performance drugs a year, so insulin's own effect can't be separated out. GH secretagogues push glucose the other way, and no study has looked at the combination.

Peptides vs. Direct IGF-1

Factor	GH Peptides	IGF-1 (LR3, etc.)
IGF-1 elevation	Moderate, through GH	High, direct
Hypoglycemia	Glucose tends to rise instead (MK-677)	Severe, with seizures (Increlex label)
Cancer concern	Theoretical; no long-term data	Malignant neoplasia in some treated children (label)
Cost	Lower	Higher
Administration	Subcutaneous	Site-specific often (user reports; untested)

Most IGF-1 sold to lifters is IGF-1 LR3, an analog with no published human data; the site rates it preliminary. Mecasermin is approved for growth failure in children with severe primary IGF-1 deficiency, and its label is the closest human safety data for the class.

Evidence for Recovery

Recovery is where peptides are most often promoted and where the human evidence is thinnest. The site rates BPC-157 as emerging: a 2025 systematic review found 35 of 36 studies were preclinical and reported no clinical safety data. TB-500 is rated preliminary, since as of October 2026 FDA says it has found no human exposure data for the fragment. Ipamorelin is rated moderate on limited human data, including a Phase 2 trial that missed its primary endpoint. We found no recovery trials for the traditional anabolics on this page either.

Side Effect Profile Comparison

Substance	Documented problems	Source type
GH Peptides	Appetite, mild edema, muscle pain, higher fasting glucose (MK-677)	Trial
HGH	Soft tissue edema and fatigue more often than controls	Systematic review
Insulin	Hypoglycemia in 57% of 41 users	Online survey
IGF-1 (mecasermin)	Severe hypoglycemia; malignant neoplasia cases	FDA label
IGF-1 LR3, TB-500	No human safety data	Regulatory

No study has compared how reversible these effects are. Our page on long-term health implications covers what's known about sustained use.

Practical Considerations

Complexity of Use

Substance	Monitoring Needs
GH Peptides	Fasting glucose and insulin sensitivity (MK-677 trial)
HGH	Swelling and fatigue (2008 review)
Insulin	Blood glucose, constantly
IGF-1	Blood glucose; the label ties dosing to meals

Our guide to monitoring protocols covers the blood markers users track.

Stacking Compatibility

Forum guides often describe peptides stacked with AAS or HGH as synergistic, and some add insulin. No controlled trial has tested any of these combinations.

Cost and WADA Status

We didn't verify current prices, so this page gives no dollar figures. Forum comparisons generally describe secretagogue vials as cheaper per month than HGH, with wide variation by source.

Substance	WADA 2026 section
GH secretagogues, CJC-1295	S2.2.4
HGH, Fragment 176-191	S2.2.3
IGF-1 (incl. LR3), MGF, TB-500	S2.3
BPC-157	S0
MOTS-c	S4.4.1
Insulin	S4.4.2
AAS	S1.1

As of October 2026, WADA's 2026 Prohibited List bans all of these at all times. Our page on peptides and sports rules explains testing.

Reported Use Patterns

Forum guides list consistent reasons for each choice. These are user rationales, not findings.

Reasons Given for Peptides

Safety is a priority (secretagogues do show shorter side-effect lists in trials, but the glucose effect is real)
Recovery/healing is the goal (mostly animal data)
Long-term use is planned
Minimal hormonal disruption desired

Reasons Given for Traditional Anabolics

Maximum muscle gain is the goal
Competing in bodybuilding
Experienced with PED use
Accepting of higher risks

Many guides describe a progression from peptides to AAS, then HGH and insulin. No study has tested whether any order changes risk.

What We Still Don't Know

No trial has compared a GH secretagogue with HGH in trained adults.
IGF-1 LR3 and the TB-500 fragment have no published human data.
As of October 2026, the first registered BPC-157 trial in rotator cuff repair (NCT07803250, about 30 patients) is not yet recruiting.

Peptides and traditional anabolics serve overlapping but distinct roles. Peptides are often called a safer entry point with strong recovery benefits, but the evidence supports a narrower claim: secretagogues have shorter documented side-effect lists in limited trials, while the recovery case rests mostly on animal data (BPC-157 emerging, TB-500 preliminary). Many experienced lifters use both, according to forum reports and the 2012 insulin survey.